Alentis Therapeutics AG has received FDA clearance of the company’s IND application for ALE.C04, a first-in-class monoclonal antibody developed to specifically target exposed Claudin-1 (CLDN1) on cancer cells.
Bruton tyrosine kinase (BTK) is involved in cell proliferation and survival in B-cell malignancies. Both covalent and noncovalent BTK inhibitors are in place, but their clinical benefit may be limited due to acquired BTK mutations.
In recent work, researchers from Mount Sinai School of Medicine applied a drug repurposing approach to identify candidates that could target inflammation in atherosclerosis.
New research shows base and prime editing can correct some forms of phenylketonuria (PKU) in mice and human cell lines, raising the prospect that this gene-editing approach could allow children born with the inherited metabolic disorder to have a treatment that would avoid the need for dietary restrictions and medication.
Two new polio vaccine candidates designed to prevent the emergence of vaccine-derived virulent polioviruses have been shown to induce immune responses in mice, raising the possibility of eradicating the virus. For that to happen, the transmission of all poliovirus serotypes must be blocked. However, the vaccine used to control polio prevents disease but does not stop transmission, enabling the virus to mutate and regain virulence.
MD Biopharm Co. Ltd. has described protein-glutamine γ-glutamyltransferase 2 (TGM2) inhibitors reported to be useful for the treatment of cancer, celiac disease, neurological, inflammatory and cardiovascular disorders.
Edgewise Therapeutics Inc. has divulged pyridazinone compounds acting as myosin-2 (MYH2) (ATPase activity) inhibitors reported to be useful for the treatment of Duchenne muscular dystrophy, amyotrophic lateral sclerosis, encephalitis, spinal cord injury, phenylketonuria, cerebral palsy, Alzheimer’s disease and Parkinson’s disease, among others.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has identified kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.
Researchers from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, Parkinson’s disease and Alzheimer’s disease.
RSS
